


Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: :




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_marc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Levothyroxine
EMR 200125-001


Bioequiv EMR200125-001 Page 1210 of 1628 lation vs. old formulation

Merck Serono
EMR 200125-001

Page 21 of 216
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




0: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number: .




0: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: .




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
 15.4.2.11.sas



Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: .




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population;
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
 15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: .




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1238 of 1628 alation vs. old formulation


Merck Serono
EMR 200125-001

Page 49 of 216

Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population;
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
 15.4.2.11.sas




Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:





Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas

Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number: ..



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number: ---



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas




Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas




Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure 15.4.2.11.sas

Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure 15.4.2.11.sas

Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas




Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas




Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1274 of 1628 ulation vs. old formulation


Merck Serono
EMR 200125-001

Page 85 of 216

Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (For Total T3 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/s210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:




⊘: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: 1



@: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:




⊘: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure 15.4.2.11.sas



Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
 15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas




Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.gas



Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




8: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas

